Publication
Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.
Martin Schrappe, Franco Locatelli, Maria Grazia Valsecchi, Gerhard Zugmaier, Michaela Vossen-Gajcy, Jan Starý, Andishe Attarbaschi, Anja Möricke, Jean-Pierre Bourquin, Draga Barbaric, Sarah Elitzur, Daniela Silvestri, Alexandra Kolenova, Luciano Dalla-Pozza, Nicole Bodmer, Martin Stanulla, Julia Alten, Faraz Zaman, Anke Bergmann, Giovanni Cazzaniga, Monika Brüggemann, Barbara Buldini, Rolf Köhler, Grazia Fazio, Claudia Rössig, Lucie Sramkova, Rosanna Parasole, Patrick Hundsdörfer, Maria Caterina Putti, Arndt Borkhardt, Franca Fagioli, Laura Rachele Bettini, Fiona Poyer, Arend von Stackelberg, Luciana Vinti, Valentino Conter, Martin Zimmermann, Carmelo Rizzari, Gunnar Cario, Andrea Biondi, AIEOP-BFM ALL 2017 Consortium
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Blinatumomab, a bispecific T-cell engager targeting the CD19 antigen on B cells, may offer an option to safely replace cycles of traditional chemotherapy in pediatric patients with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL). METHODS: We randomly assigned, in a…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT03643276registry_reference1.00
Candidate 1
- cancerLeukemiadictionary0.60
Registered trialsNCT03643276
Curated evidence
Evidence citing this paper (0)
Data not yet available